This chapter examines recent progress on public health and prevention, quality of care, hospital financing and pharmaceuticals. Despite some encouraging developments in recent years, public health and health promotion in Switzerland remains largely uncoordinated and varies in line with cantonal policies and capacities. As debate has continued over a new prevention law, progress has been slow in promoting cost-effective health prevention policies or expanding coverage of successful prevention measures – such as breast cancer screening. Similarly, while recent efforts to expand collection of quality of care data are worthwhile, there remains a need for nationally consistent data collection to determine whether Swiss people are indeed receiving best practice health care. Switzerland’s move to a casebased financing of inpatient hospital services is a positive move that should help improve efficiency. The extent to which it does so will critically depend on how individual cantons implement these reforms. Pharmaceutical policies have met some success, though more could be done to increase value for money.